Suchergebnisse - "Breccia, Massimo"

PubPharm (11)

1

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors

enthalten in: British journal of haematology | 2018

von Molica, M. | Canichella, M. | Colafigli, G. | +5

2

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice : Identification of risk factors and the role of prophylaxis

enthalten in: American journal of hematology | 2018

von Caocci, G. | Mulas, O. | Annunziata, M. | +33

3

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

enthalten in: Health and quality of life outcomes | 2017

von Breccia, M. | Baccarani, M. | Rosti, G. | +5

4

Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy

enthalten in: American journal of hematology | 2015

von Breccia, M. | Stefania de Propris, M. | Molica, M. | +7

5

Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront

enthalten in: Leukemia & lymphoma | 2015

von Breccia, M. | Molica, M. | Colafigli, G. | +4

6

FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols : long-term follow-up analysis

enthalten in: Haematologica | 2013

von Breccia, M. | Loglisci, G. | Loglisci, M. | +5

7

Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences

enthalten in: Leukemia research | 2011

von Breccia, M. | Loglisci, G. | Cannella, L. | +4

8

A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia

enthalten in: Annals of hematology | 2011

von Gianfelici, V. | Diverio, D. | Breccia, M. | +7

9

Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy

enthalten in: Leukemia research | 2010

von Breccia, M. | Santopietro, M. | Loglisci, G. | +4

10

Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months

enthalten in: Acta oncologica (Stockholm, Sweden) | 2010

von Cannella, L. | Breccia, M. | Loglisci, G. | +3